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Chronic Treatment with Ami~ptyline Produces 
Supersensitivity to Nicotine 
Steven C. Dilsaver, Mark J. Majchrzak, and Norman E. Alessi 
The authors used a thermoregulation paradigm to evaiuate ejgkcts of amitriptyiine (AM) 
on the sensitivity of a nicotinic mechanism involved in the regulation of core temperature 
in rats. Treatment with this tricyclic was associated with a signiQicant increase in the 
hypothermic response to nicotine. Supersensitivity persisted for a minimum of 7.5 days 
following the last dose of AMI, and a significant proportion of animals displayed increased 
sensitivity after 14 .S days of abstinence. ~rnp~i~atio~ for the melanism of action of AM 
are highlighted. 
Introduction 
Tricyclic antidepressants (TCAs) directly bind to muscarinic acetylcholine receptors 
(mAchRs) and produce blockade of muscarinic mechanisms (Dilsaver 1986a). Supersen- 
sitization of these mechanisms is an effect of agents that directly block access of ace- 
tylcholine (Ach) to the postsynaptic mAchR or inhibit its release (Dilsaver et al. 1987). 
We reported that a~~p~line (AMI), 10 mglkg twice daily for 12 days, increased 
sensitivity to the hypothermic effects of oxotremorine (0X0) in rats (Dilsaver et al. 
1987). Although their muscarinic effects have been thoroughly investigated, influences 
of these agents on parameters influenced by nicotinic mechanisms have received little 
attention. 
Nicotinic and muscarinic agonists may act at receptor sites that have mixed muscarinic- 
nicotinic responsiveness (Morley and Kemp 1981). Westfall (1973) observed that a mus- 
carinic agonist blocked the release of norepinep~ne in the rat h~thal~us, whereas a 
nicotinic agent increased its release. Thoenen et al. (1973) reported that increased pre- 
ganglionic (i.e., nicotinic) neurotransmission enhanced the activity of tyrosine hydrox- 
ylase in noradrenergic neurons. Increased nicotinic neurotransmission lasting 60 min 
increased the level of tyrosine hydroxylase activity 48 hr later. The findings that nicotine 
releases catecholamines and that nicotinic neurotransmission increases the activity of the 
enzyme governing the rate-limiting step in catecholamine synthesis are consistent with 
the hypothesis that decreased noradrenergic and dop~inergic function are involved in 
the pa~o~ysiolo~ of depressive disorders. 
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Methods 
This report includes three experiments. Experiments 1 and 2 involved the measurement 
of change in core temperature in response to challenge with nicotine (base), I mg/kp. 
ip, before and after treatment with AMI, 15 mg/kg, ip, twice daily for 7 days. The second 
experiment replicated a portion of the first. A third experiment involved measurement of 
the hypothermic response to four doses of nicotine (base), 1 mg/kg. which were injected 
at 7-day intervals. This experiment was based on the possibility that multiple injections 
of nicotine could produce carryover effects that confound our data. All three experiments 
involved adult male Sprague-Dawley rats. Experiments 1 and 2 required single samples 
that weighed 294 t 1.1 g (mean t SEM. n = 10) and 289 t 6.7 g (mean rt SEM, II 
= 7). respectively. The third experiment involved 8 animals weighing 301 rt 9.4 g. 
Measurement of Core Body Temperature 
Model VM Mini-Mitters (Mini-Mitter Co., Sun River, OR) were surgically implanted 
into the peritoneal cavity. These instruments emit radio waves at a rate proportional to 
temperature. A transistor radio set to an AM frequency served as a receiver. Time to 
emit 10 sounds was measured using a digital display stopwatch. This measurement was 
converted to temperature using a linear regression equation that was derived by measuring 
the emission rate of each instrument at three different temperatures in a temperature- 
controlled water bath. Tocco-Bradley et al. (1985) established the validity of this method. 
Nicotine Challenge 
Nicotine challenges were conducted at the same time of day. The first challenge preceded 
the initiation of treatment with AM1 by 24 hr. The second challenge occurred 12 hr after 
the last dose of AMI. Temperature was measured immediately prior to and every 10 min 
after the injection of nicotine (1 mg/kg). Baseline temperature for a given challenge is 
defined as the temperature immediately prior to the injection of nicotine. Temperature 
was recorded every 10 min for 120 min. 
Pharmaceuticals 
AMI and nicotine were purchased from Sigma Chemical Company (St. Louis, MO). 
Nicotine doses refer to the base form. Dose of AM1 refers to the salt form. Both agents 
were administered intraperitoneally on a milligram per kilogram basis. 
Experimental Design: Study I 
This study was divided into three phases. In Phase 1, the thermosensors were implanted 
into 10 animals, and the animals were then allowed 5 days to recover. During Phase II, 
the baseline hypothermic response to nicotine (1 mg/kg, ip) was measured. The animals 
then received twice daily injections (at 12-hr intervals) of AMI, 15 mg/kg. Twelve hours 
after the 14th dose of AMI, the animals were rechallenged with nicotine. Phase III, a 
drug withdrawal phase, extended over 14 days. During this period, nicotine challenges 
3 and 4 were conducted. This allowed assessment of the duration of any effect of AM1 
treatment on the hypothermic response to nicotine after the TCA was discontinued. 
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Experimental Design: Study 2 
This experiment included Phases I and II without modification, but Phase III was omitted. 
Ex~er~rn~~ta~ Design: Study 3 
Thermosensors were implanted into 8 rats, and the animals were allowed 5 days to recover. 
The sample then received nicotine (1 mg/kg, ip) every 7 days for 21 days. The thermic 
response was measured every IO min for 120 min foliowing the first and fourth injections 
of nicotine. 
Statistical Analysis 
Data from experiments 1 and 2 entering into statistical analyses were derived by calculating 
thedifference between the thermicresponse between corresponding time points across weeks 
of the study. Change in ~ern~~tu~ at each of the I2 points, difference in mean temperature 
change between challenges for each animal and each sample, and the mean difference in the 
maximum hypothermic response between challenges were assessed for significance. Mean 
change in core temperature was the dependent variable in experiment 3. 
The Student’s paired r-test was used to assess level of significance in mean response 
at each of the 12 time points in experiments 1 and 2. Availability of data on the thermic 
response of each animal at 12 time points before and after treatment with AM1 allowed 
us to determine whether or not the responsiveness of individual animals to nicotine was 
altered using Student’s paired ?-test. Significance of the difference in mean response was 
also determined using Student’s paired t-test in experiment 3. 
The binomial test was applied to calculate &he probability of a given number of animals 
exhibiting statistically significant responses at any given level of a. SiegeI (1956) outlined 
the principles governing the use of this test. The Sign test was used to determine the 
probability of a sample exhibiting an increase to the hypothermic response to nicotine at 
a given proportion of time points (Siegel 1956). 
Results 
Experiment I 
Mean maximum hypothermic response. One week of treatment with AM1 was asso- 
ciated with a significant increase in the mean maximum hypothermic response of 1.21 
+ 0.12”C (mean + SEM; p < 0.001). The mean maximum response remained elevated 
1 (1.31 ~fr 0.23”C; p < 0.001) and 2 (1.00 & 0.3S’C; p < 0.02) weeks after the 
discontinuation of AMI. 
Change in the hypothermic response at ind~v~d~l time points. One week of treatment 
with AMI was associated with a significant enhancement of the hypothermic response 
10 @ c 0.02), 30 (p < 0.05), 40 @ < O.Ol), 50 @ < O.OOl), 60 (p < 0.051, and 120 
(p < 0.01) minutes after the injection of nicotine. There was an increase in the hy~the~ic 
response at all 12 time points (p = 0.002, Sign test). 
There was significant enh~cement of the hypothermic response at three points after 
1 week of abstinence (p = 0.0029, binomial test) and an increase in the response at all 
12 points (p = 0.0002, Sign test). No point exhibited a significantly enhanced hypo- 
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thetmic response after 14.5 days of abstinence, but the hypothermic response was In- 
creased at 9 points (p = 0.045, Sign test). 
Change in the hypothermic response across weeks. Change in the thenic response 
to nicotine over the 4 weeks of this experiment was evaluated by assessing the significance 
of the mean reduction in core temperature relative to baseline. Mean reduction in core 
temperature (“C) after 7 days of treatment with AM1 relative to the pre-AMI baseline 
was 0.46 & 0.1.X (p < 0.02); after 7.5 days of abstinence, it was 0.54 ‘-+ 0.2O”C 
(p < 0.05); and after 14.5 days of abstinence 0.19 -+ 0.19”C (NS). Tables 1-3 sum- 
marize data of the mean hypothermic response for each week of experiment 1 for each 
animal and the sample as a whole. 
Experiment 2 
Maximum hypothermic response. Treatment with AMI was associated with an in- 
crease in the mean maximum hypothermic response to nicotine of 0.69 t 0.16”C 
(mean 2 SEM; p < 0.001). The maximum response to nicotine was greater after treatment 
in all animals (p = 0.0039, Sign test). 
Change in the hypothermic response across time. The sample demonstrated an increase 
in the hypothermic response across time of 0.52 It O.IO”C (mean f SEM; p < 0.01). 
Experiment 3 
The mean hypothermic response to nicotine was 1.37 5 0.23”C (n = 8) when the sample 
was first challenged with nicotine (1 mg/kg, ip) and I .32 t- 0.2O”C (n = 8) after the 
fourth challenge (NS, t = 0.67, df = 7). 
Table 1. Mean Reduction in Core Body Temperature (“C) (Average for Each IO-min Point from 
10 to 120 min Postinjection of Nicotine) +- SEM in Response to Nicotine (1 mg/kg. ip) 12 hr 
after the Discontinuation of a Course of Amitriptyline Hydrochloride (15 mg/kg. ip. Twice 
Daily for 7 Days) Relative to the Preamitriptyline Baseline 
Animal 










-- 0.57 0.09 
+0.34 0. I8 
-0.49 0.15 
-- 1 20 0.15 











-- 2.93 <0.02 
-X.83 10.001 
4 0.95 NS 
- 4.69 <O.Ol 
- 2.4 <o.os 
-- I 79 NS 
- 2.48 <o.os 
+ 1.54 NS 
- 3.30 co.02 
-- 13.30 <o.ooi 
-3.07 co.02 
The 98% confidence interval for this mean is 0.46 t 0.42. 
The probability of 7 or more animals out of 10 exhibiting enhanced responses to nicotine is 6.6 x IO ‘” when the critical 
value of I is set to a < 0.05 (Siegel 1956). 
Nicotine Supersensitivity from Amit~ptyline BIOL PSYCHIATRY 173 
1988;~16~~75 
Table 2. Mean Reduction in Core Body Temperature (“C) (Average for Each 12 Time Points 
from 10 to 120 min t SEM) in Response to Nicotine (1 mgkg, ip) 7.5 Days after the Last Dose 
of Amitriptytine Hydrochloride 
Animal 
no. Mean SEM df t P 
1 +0.27 0.18 
2 -0.63 0.15 
3 -0.61 0.11 
4 -0.47 0.16 
5 + 0.04 0.21 
6 -0.08 0.07 
7 -1.68 0.20 
8 +0.44 0.21 
9 -1.02 0.20 
10 -0.81 0.19 












+ 1.5 NS 
-4.20 CO.01 









The 95% cwlidence interval for this mean is 0.54 t 0.45. 
The probability of 6 or more animals out of 10 exhibiting significant enhancement of hypothermic responses (at u < 0.05) 
to nicotine is 4.6 x 10-8. 
The probability of 1 or mom animals exhibiting a significant rise in the thermic nsponse to nicotine is 0.25. 
Discussion 
These data indicate that AMI produces supersensitivity to nicotine. This effect occurs 
within 7 days of starting treatment with AMI and slowly decays after it is discontinued. 
Although the mean hypothermic response relative to the pre-AMI baseline was not sig- 
nificant after 14.5 days of abstinence, 5 of 10 animals still exhibited a significant increase 
in the hypothermic response (p = 2.2 x 10-6, binomial test) (Siegel 1956). Furthermore, 
Table 3. Mean Reduction in Core Body Temperature (“C) (Average for Each 12 Time Points 
from 10 to 120 min 2 SEM) in Response to Nicotine (1 mgikg, ip) 14.5 Days after the Last 
Dose of ~i~ptyline Hy~hlo~de 
Animal 
110. Mean SEM 
1 +0.44 0.19 
2 -0.11 0.27 
3 -0.91 0.17 
4 - 0.54 0.16 
5 + 0.95 0.12 
6 -1.32 0.35 
7 -0.20 0.09 
8 +0.86 0.20 
9 -0.01 0.16 
10 -1.06 0.22 
df t P 
11 -I-2.44 (CO.05) 
11 -0.38 NS 
11 -4.3 CO.01 
11 -2.8 CO.02 
11 +6.39 (<O.OOl) 
I1 - 8.25 <O.Wl 
11 -2.22 CO.05 
11 +3.44 (CO.01) 
11 -1.0 NS 
11 -5.36 <O.ool 
Mean + SEM = 0.19 C 0.19 9 -0.79 NS 
The probability of 5 or more animals out of 10 exhibiting significant enhancement of the hypothermic response-s to nicotine 
is 2.17 X IO+. 
The- probability of 3 or more animals exhibiting a significant rise in the therrnic response to baseline is 0.003. 
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the maximum hypothermic response remained elevated. This suggests that treatment with 
AMI produced prolonged supersensitivity to the hypothermic effects of nicotine. Obser- 
vation that the injection of nicotine at 7-day intervals did not produce a carryover effect 
suggests that the decrease in thermic responsiveness following the discontinuation of AMI 
is due to the decay of a pharmacological effect of the TCA and not an artifact of design. 
Schofield et al. (1981) found that AM1 and nortriptyfine produced a voltage- and timc- 
dependent decrease in the peak amplitude of the end-plate current in frog skeletal muscle. 
They proposed that the primary site of action is the ion channel. Similarly. Slaker et al. 
(1981) presented evidence that imipramine binds to sites on the ionic channel of the 
nicotine receptor of the Torpedo electric organ. However, the results reported here are. 
to our knowledge, the first indicating that a TCA alters a nicotinic mechanism in a 
mammalian species. 
Nicotine promotes the release of dopamine in the nigrostriatal and mesolimbic tracts 
(Andersonn et al. 198 1) and triggers the release of norepinephrine in the hy~thaiamus 
(Westfall 1973). Activation of mAchRs in the peripheral ganglia increases the activity 
of tyrosine hydroxylase (Thoenen et al. 1973). Thus, the findings reported here are 
consistent with the hypothesis that TCAs potentiate monoaminer~ic mechanisms via 
effects on nicotinic mechanisms. 
It would be advantageous to study the hypothermic effects of nicotine in animals in 
which a highly effective, yet nontoxic, nicotinic antagonist of nicotinic receptors in the 
periphery is employed. An agent with this selectivity may not exist. Ganglionic blockade 
produces vasodilitation, which can produce heat loss. Secondly, it is important to deter- 
mine the degree to which our findings can be applied to other somatic treatments and 
physiological paradigms before their importance can be determined. 
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